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1402Combined Submyeloablative and Myeloablative
Dose Intense Melphalan Results in Satisfactory
Responses with Acceptable Toxicity in Patients
with Multiple Myeloma
Nicolas Novitzky,1,2 Jaqueline Thomson,1 Valda Thomas,2 Cecile du Toit,1,2
Zainab Mohamed,3 Andrew McDonald1,2We studied in patients with multiple myeloma (MM) the efficacy, cost-effectiveness, and toxicity of a strategy
of submyeloablative doses of Mel and stem cell support in the ambulatory setting, followed by a standard
myeloablative dose transplant. Patients with recently diagnosed symptomatic MM received dexamethazone
to induce clinical response. Cytokine mobilized peripheral blood progenitor cells (PBPC) were split into 2
aliquots and cryopreserved. Patients then received Mel 100 mg/m2 (Mel100) and infusion of the first
PBPC aliquot in an ambulatory facility. Individuals received standard neutropenia prophylaxis and no growth
factor support, but were seen regularly at the clinic until recovery. The cost of this step was calculated in
a cohort of 23 patients where information for the expenditure was available. Six months later patients
were conditioned in the hospital with Mel 200 mg/m2 (Mel 200) followed by nfusion of the second aliquot.
This study tested the cost, effectiveness, and the toxicity of out-patient-based transplantation, as well as the
rate of response (complete remission [CR], very good partial remission [VGPR], partial remission [PR], and
stable disease [SD]) and overall survival (OS) of this strategy. Twenty-six female and 16 male patients, with
a median age of 53 years (range: 33-68 years) andmedian Salmon &Durie clinical disease stage III (range: II-III)
were studied. The paraprotein was IgA in 17%, IgG in 52%, and light chains in 26%. The median harvested
CD341  106 cells/kg was 12.03 (2.25-55.4). The median interval between the 2 transplant procedures
was 239 (105-376) days. The median Karnofsky presentation score was 40%, but improved to 80% after
the Mel 100 and was 90% following Mel 200. Subsequent to MEL 100 response was complete (CR) in 7
and it was VGPR in 9. Mel 100 grade 3-4 toxicity was mainly hematologic, but 15 (36%) required hospital
admission for a median of 5 days. The median cost of MEL100 and corresponding supportive therapy was
U.S. $2,142.35. In addition, the total median cost of those who needed admission to hospital was
U.S. $6,042.78. Thus, pooling costs from patients who needed or did not need admissions the average
cost of this strategy was U.S. $3,546.50 per patient. Among Mel 200 patients, except for hematologic toxicity,
no patient had greater than grade 2 side effects. On completion of the program, 20 (48%) patients achieved
CR, a further 14 (33%) had VGPR, whereas 6 had PR. At a median follow-up of 659 days there were 8 deaths,
1 (2%) was related to the treatment procedures and 6 from disease progression; thus, the 1000 days OS was
73%. Significant adverse factors included older age, lower presentation Hb, and lower Karnofsky %. Non-
parametric testing confirmed that good performance scores and VGPR or CR were associated with more
favorable outcome. Importantly, these satisfactory results were obtained in the absence of the new biologic
cell modifiers. Mel 100 was well tolerated in the outpatient setting and the overall strategy seems to be ef-
fective in inducing durable responses with acceptable toxicity.
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Despite substantial progress in our understanding
of the biology of multiple myeloma (MM) and the
availability of new treatment modalities, it still remains
essentially an incurable disease. Over the last 20 years,
a number of strategies have been developed that have
resulted in significant improvement in the control of
the malignancy, and even leading to complete remis-
sions in a significant fraction of patients. These strate-
gies include the introduction of dose-escalated
melphalan (Mel) with autologous stem cell transplan-
tation (SCT) [1-4], and more recently, disease
modulation with biologic cell modifiers such as
thalidomide [5], lenalidamide [6], and bortezomib
[7], alone or in combination with corticosteroids and
cytotoxic agents [8]. Thus, with these emerging
options, the optimal management of symptomatic
patients still remains to be defined; however, because
myeloma still constitutes an incurable disease, both
improvement in the length and the quality of life
must be equivalent goals. Yet, for those who do not
have contraindications, autologous SCT remains the
gold standard in the management of this condition.
Following high-dose therapy there is rapid control of
the malignancy, and around 50% of patients may
show no morphologic or chemical evidence of the
disease, a state that has been associated with improve-
ment in survival [3,8,9]. As for the older population,
this procedure is still associated with substantial
morbidity. Palumbo and colleagues [10] tested lower
doses of dose-intense Mel (submyeloablative; 100
mg/m2) and also observed substantial responses with
lower toxicities [10]. In addition, a number of investi-
gators have shown that long-term survival was associ-
ated with good response to this therapy, and that for
certain patients, 2 transplants, in tandem, increased
the rates of such favorable responses [11-14].
We, therefore, describe a stepwise therapeutic
approach where patients with symptomatic myeloma
were offered induction therapy with dexamethasone,
followed by harvesting of sufficient stem cells for 2
autologous SCTs. The first conditioning was with
intermediate dose melphalan (melphalan 100 mg/m2
[Mel 100]), followed by the infusion of the first ali-
quot of autologous stem cells. Patients were fully
managed in the ambulatory setting. We calculated
the costs of this intervention to determine cost
effectiveness compared to current modalities. Once
individuals recovered from the initial therapy,
approximately 6 months later, they received the sec-
ond full dose conditioning (melphalan 200 mg/m2
[Mel 200]) in a high-care ward. We show here that
this strategy was associated with good disease control,
was well tolerated, and has resulted in encouraging
long-term outcome.PATIENTS AND METHODS
Definitions and Diagnostic Criteria
Between 2003 and 2008, patients with Salmon &
Durie stage II or III [15] symptomatic MM, aged up
to 65 years and Karnovsky performance status .30%
were eligible for the study. Consent for therapy was ob-
tained according to the directives of the University of
Cape Town. Diagnosis of MM was made in line with
the criteria of the Chronic Leukemia-Myeloma Task
force [16]. Entry conditions were symptomatic disease
in patients who had no contraindications for intensive
chemotherapywith high-doseMel, aswell as acceptable
vascular access to undergo apheresis. Exclusion factors
were cardiac ejection fraction of\45%, vital pulmonary
capacity of \45% of the predicted value, estimated
creatinine clearance of\30 mL/min, active hepatitis
B or C virus infection or HIV reactivity, as well as un-
controlled epithelial cancer or psychiatric disease. The
primary objectivewas to determine the efficacy and tox-
icity of ambulatory conditioningwith submyeloablative
dose-intensified Mel followed by SCT. The secondary
end points were to quantitate the rate of complete
remission (CR), disease free survival (DFS), and overall
survival (OS) for this strategyof tandemtransplantation.
We also attempted to calculate the costs of this
outpatient strategy in the South African setting. Study
population included newly diagnosed patients with
MM who were treated with a steroid-based induction.Supportive Measures
Groote SchuurHospital is a state health institution
that serves mainly patients without medical insurance.
Patients are often in need of financial assistance to be
able to attend hospital visits and have limited family
support. To participate in the current program
patients underwent a psychosocial evaluation to deter-
mine their ability to care for themselves, their under-
standing of the complexities of this protocol, to make
certain of their compliance, as well as to ensure that
they had adequate family support. Individuals were
required to have a care giver readily available, to test
their body temperatures every 8 hours, and have easy
access to the hospital. For all patients receiving initial
therapy, usual neutropenia prophylaxis applied. Fol-
lowing submyeloablative conditioning and graft infu-
sion, patients were requested to attend the clinic
3 times a week to detect possible complications of
leukopenia and for evaluation of nausea and oropha-
ryngeal mucosal damage (mucositis) by chemotherapy.
Uncontrolled nausea and vomiting despite serotonin
inhibitor antiemetics, pyrexia higher than 38C, or
clinical manifestations of malnutrition/dehydration
from mucositis were all indications for prompt
admission to the hospital.
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Recently diagnosed patients with symptomatic
MM were treated with dexamethasone 40 mg daily
on days 1-4, 8-11, and 18-21, every 28 days for 4 cycles.
After the completion of the fourth series of dexameth-
asone and of the corresponding treatment response
evaluation, regardless of initial outcome, patients
underwent stem cell mobilization as an ambulatory
procedure. Mobilization chemotherapy consisted of
etoposide 1 g/m2 on each of 2 consecutive days.
Patients were taught to inject and received filgrastim
(Neupogen, Roche Pharmaceuticals, Indianapolis,
IN, USA) 300 mg subcutaneously twice daily for 7-10
days, starting on day 5. On day 14 following mobiliza-
tion chemotherapy, peripheral blood progenitor cells
(PBPCs) were enumerated according to ISHAGE rec-
ommendations [17] and apheresis was commenced
once CD341 cell count exceeded 5  106/mL. Apher-
esis was undertaken with continuous cell separator
(Cobe Spectra, NJ, USA) and enough progenitor cells
for 2 procedures were collected. The minimum target
CD341 was 2  106/kg, per graft.
After premedication with allopurinol 300 mg, par-
enteral prehydration andantiemetics, patients had a sin-
gle intravenous infusion of Mel 100 in the clinic.
Twenty-four hours later cryopreserved PBPC were
thawed in a 37C water bath and the first aliquot of
stem cells was rapidly transfused in the outpatient
section. Oral neutropenia prophylaxis consisted of
ofloxacin 200 mg twice a day and daily fluconazole
(400 mg); antiemetic agents were continued for 72
hours or while patient remained symptomatic. Individ-
uals receiving the first graft were then requested to
attend the clinic on alternate days until recovery of neu-
tropenia. Hematopoietic growth factors were not
offered. Approximately 6 months following the initial
transplant, patients withMMwere admitted to the pro-
tected environment unit atGroote SchuurHospital and
a siliconized double lumen indwelling catheter [18] was
inserted percutaneously into the internal jugular
vein. Patients were prescribed similar protective
measures and neutropenia prophylaxis as for the initial
conditioning chemotherapy. For the second transplant,
patients receivedMel 100 mg/m2 on each of 2 consecu-
tive days (total dose 200 mg/m2;; MEL 200), as
a 30-minute infusion.Evaluation of Response
Evaluation of response required review of the bone
marrow (BM) plasmacytosis, protein electrophoresis
with immunofixation, as well as determinations of b2
microglobulin and of serum chemistry, which were
performed at 8-12 weeks after the first and second
autologous transplants [19]. Part of this evaluation
included determination of the changes in the perfor-
mance status using Karnovsky scale. Response typewas defined following the IMF recommendations
[17,20]. CR required absence of plasmacytosis from the
BM and of the serum praprotein on immunofixation.
Disease progression implied at least a 25% increase in
tumor mass, BM plasmacytosis, or any new disease
manifestation. Relapse was defined as recurrence of
monoclonal protein or BM plasmacytosis or evidence
of extramedullary disease in case of CR, very good
partial remission (VGPR), or partial response (PR),
including any new disease manifestation such as hyper
calcemia or new bone lesions. Treatment-related
mortality (TRM) included any death within 30 days
posttransplantation.
Evaluation of Costs
Most medication in the state hospital in South
Africa is procured at State Tender prices, which are
substantially lower than those charged to the general
public by private pharmaceutical drug suppliers.
Biologic agents such as thalidomide or bortezomib
are not available at state hospitals, but may be pur-
chased from pharmacies privately, or once approval
from insurance companies has been obtained. Patients
who have health insurance pay for the cost of the med-
ication at a single exit price (SEP), which is negotiated
between the pharmaceutical companies and theHealth
Department. We retrospectively determined the cost
for the induction phase with the Mel 100 program
(inclusive of value added tax) by calculating the costs
of the reagents to store the stem cells, conditioning,
and of supportive drugs applying the SEP for all phar-
maceuticals used and added the costs of consultations
at the hospital. We calculated the cost of consultations
and hospital admission tariffs according to the Depart-
ment of Health National Reference Price List
(www.doh.gov.za/docs/nhrpl-f.html) tariffs charged
by medical insurance as well as the cost of blood prod-
uct support as per Western Province Blood Transfu-
sion Service price list (www.wpbtsmedical.org.za/
images/Private09.pdf; year 2010).
Statistical Methods
Standard population statistics were employed to
define the patient population. Median cost of
outpatient and in hospital therapies for Mel 100 were
calculated. Final costs were estimated by adding the
expenses generated by hospital admissions of 15
patients to the outpatient expenses. Survival analyses
were performed using the product limit estimate of
the Kaplan-Meier method. Significance in the
difference of survival curves from various groups
was compared by the log-rank test. To predict
outcome, pretransplant variables analyzed were lactate
dehydrogenase (LDH), albumin, BM plasmacytosis,
time to second transplant, and response to salvage che-
motherapy by nonparametric statistics. Patients were
Table 1. Clinical and Laboratory Parameters of the Study
Population
Parameter Value
Age, years median (range) 53 (33-68)
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were studied for response TRM, OS, and event-free
survival (EFS) according to IMWG criteria. OS was
calculated from time of first dose of dexamethasone.Sex distribution, F/M 26/16
Parapotein type, patient No. (%)
IgA 7 (17)
IgG 22 (52)
Light chain 11 (26)
Non secretor 2 (10)
b2 microglobulin mmol/L median, (range) 2.4 (1.4-8.1)
Abnormal No. (%) 12 (29)
Salmon & Durie clinical stage, median (range) III (II-III)
ISS median, range 1 (0-2)
ISS indicates International Scoring System;19.RESULTS
Patients’ Demographic and Clinical Data
The characteristics of the patient population at en-
try are shown in Table 1. All patients had symptomatic
disease. On presentation the renal function was abnor-
mal in 10 patients, and it normalized with treatment in
all except 1. The median Karnofsky score at diagnosis
was 40% but improved to 80% after the Mel 100 and
was 90% following Mel 200 (Figure 1). As patients
progressed through the treatment sequence, improve-
ment of paraprotein level, BM plasmacytosis, Hb,
serum albumin, b2MG, and Karnofsky status can be
observed in Figure 1.
Following dexamethasone-based induction, evi-
dence of response (CR 1 VGPR 1 PR) was observed
in 25 (61%) individuals. In this group, 2 patients
achieved CR and another 3 VGPR, whereas 20 were
in PR. Disease parameters decreased by less than 50%
or remained stable in another 13 individuals; MM
progressed in 2 patients. Response data was not avail-
able in 2 individuals. Regardless of type of response,
all patients proceeded to the transplantation stage.Stem Cell Transplantation Parameters and
Treatment Outcomes
After stem cell mobilization with etoposide, the
median harvested CD341 cells/kg was 12.3 (range:
2.25-55.4; Table 2). The median number of apheresis
procedures was 1 (1-3). However, in 1 individual the
circulating CD341 cell number decreased rapidly
and PBPC available allowed only 1 transplant, which
followed a single Mel 200 conditioning. Thus, suffi-
cient CD341 cells for the 2 procedures were collected
in 40 subjects and it was with a single apheresis in 35
(87.5%) patients. There was no significant difference
in theCD341 cell number infused between the 2 trans-
plants. The median interval between the 2 transplant
procedures was 212 (105-376) days, the delay being
mainly because of logistic and operational reason
(availability of a bed for admission). One patient failed
to receive the second graft because of a vascular access
catastrophe that led to the patient’s death in VGPR.
Thus, a total of 41 patients received the first graft
and 40 individuals completed the full program.
Respectively, the median time to neutrophil and plate-
let recovery was 14 and 18 days for the first procedure
and 13 and 17 days for the second. No maintenance
therapy was prescribed until disease recurrence.All patients showed some improvement of MM
after stem cell mobilization with etoposide (and
filgrastim), conditioning with Mel 100 and infusion
of the first graft. CR was now observed in 7 patients
(5 additional), whereas 9 (6 additional) had achieved
VGPR (38% CR 1 VGPR). One patient in CR died
during the insertion of Hickman line before the Mel
200 treatment. Two individuals who had progressed
after dexamethasone now achieved PR and VGPR.
After the second graft, a stringent evaluation showed
that 20 (48%) patients achieved CR, a total of 14
(33%) had achieved VGPR, whereas another 6 were
in PR. Disease progressed in 1 subject. Compared to
the outcome of the lower intensity schedule, Mel 200
improved the response of most initially responsive pa-
tients and resulted in 81% achieving CR or VGPR.
One patient who had responded toMel 100 progressed
rapidly after Mel 200. At relapse patients were treated
with various alkylators, biologicals, or anthracycline-
based combinations. One patient died followingmotor
vehicle accident. At the time of the analysis, 5 had
progressed but had stable disease on further therapies
and 6 patients had died of progressive multiple
myeloma. At 8-12 weeks followingMel 200, plasmacy-
tosis .10% was detected in 5% (n 5 40; Figure 1A).
At a median follow-up of 648 days, there were
8 deaths: 1 (2%) was directly related to the treatment
procedures, 1 from a motor vehicle accident, and
6 from disease progression (Table 2). Median survival
has not been reached. For the complete cohort, the
1000-day survival is 73% (Figure 2A). Figure 2 shows
that there was significant difference in survival
between the 3 response groups, with CR or VGPR
resulting in better outcome compared to the PR group
(Figure 2B; P 5 .01). On multivariate analysis,
significant adverse factors for survival included lower
(than median) Hb on presentation (P \ .01), lower
Karnofsky % (P\ .01), and older age (P 5 .04).Toxicity (Table 3)
Toxicity of dexamethasone was predictable, of
mild nature, and was well controlled with standard
Figure 1. Graphical representation of the laboratory parameters and of Karnofsky scores at the different stages of the described therapeutic strategy.
All the values are significantly different from the presentation parameters. (Dexa: dexamethasone; SCT 1 and 2: stem cell transplant 1 and 2).
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Table 2. Autologous Stem Cell Transplantation in Tandem:
Cause of Death and Overall Survival
Treatment Outcome (No. 42)
All deaths: 8
TRM 1
Other 1
Progression of myeloma 6
Follow up, median days 648 (111-1824)
% surviving 75%
% in response 41%
TRM indicates treatment-related mortality; OS, overall survival.
Biol Blood Marrow Transplant 16:1402-1410, 2010 1407Ambulatory Stem Cell Transplantation in Multiple Myelomasupportive measures. Mobilization of CD341 cells
with etoposide at 2 g/m2 gave mainly hematologic
and gastrointestinal toxicities. All patients developed
severe (grade 3-4) neutropenia; 5 patients were admit-
ted with neutropenic fever and all responded to antibi-
otics. Grade 2 mucositis occurred in 18 individuals,
but none showed grade 3 or 4 toxicities. All underwent
stem cell harvest without delays.
The toxicity ofMel 100 was manageable in the out-
patient setting (Table 3). All patient developed grade
4 hematologic toxicities and 10 individuals required
transfusion of red cells (median 2 units) and, in 6 cases,
ofplatelets (median1 singledonorunit).Fifteenpatients
required admission to hospital, mainly for neutropenic
fever, for a median of 5 days. One patient in VGPR
and normal blood parameters died of bleeding during
the insertion of a Hickman line before the second trans-
plant.Mel 200was associatedwith the usual side effects,
but except for hematologic toxicity, no patient had
greater than grade 2 side effects.Therewas nomortality
after conditioning with Mel 100 and Mel 200.
Cost of Therapy
The expenditure of Mel 100 induction therapy
received by 23 individuals where detailed drug usageFigure 2. OS of the study population. (A) Shows the overall outcome. (B) Sho
egy. Patients who failed to achieve at least VGPR had significantly worse outcowas available was calculated. The median cost of Mel
100 and corresponding supportive therapy was
R 16,281.80 (range: 15,441.14-3278.60) or U.S.
$2,142.35 (1Rand: 7.60 U.S. $). In addition, the total
median cost of those who needed admission to hospital
(in a private facility) for the typical complications was
R 45,925.10 (U.S. $6.042,28). Thus, because 36%
required admission for complications of dose intense
Mel 100 for a median of 5 days, the average cost until
recovery of this strategy pooled from 10 patients who
needed or did not need admissions was R 26,953.40
(U.S. $3,546.50).DISCUSSION
The combination of oral Mel and prednisone has
been the mainstay in the treatment for patients with
MM for 4 decades. Other cytotoxic combinations
such as infusional vincristine, adriamycin, and high-
dose dexamethasone (VAD) [21], etc., have also been
explored but in a meta-analysis, these more complex
schedules did not significantly improve survival [22].
Moreover, dexamethasone appears to be themost active
ingredient in the VAD combination leading to similar
outcomes as the substantially more complex and
toxic 3-drug combination. Nevertheless, most patients
will experience disease recurrence and then further
management remains unsatisfactory. For this reason,
in a prospective randomized study, the Intergroup
Francophone pour l’etude du Myelome (IFM) showed
that inmyeloablative dosesMel followed by autologous
stem cell infusions was associated with significantly
better responses and more extended survival than
standard dose salvage therapy [3]. Thereafter, these
and other investigators suggested that 2 autologous
transplants in tandem led to superior DFS and OS,ws the outcome according to type of response to the therapeutic strat-
me.
Table 3. Toxicity Scores of the Mel 100 and Mel 200 Condi-
tioning Programs
Mel 100
(n 5 41)
Mel 200
(n 5 40)
Mucositis (WHO) patient No.
I 7 6
II 12 25
III-IV 0 9
Fever >38 C 15 38
Number of hospital admissions 15 40
Days in hospital, median (range) 5 (4-9) 17 (14-28)
Blood component support median, (range)
Platelets 1 (0-6) 4 (1-11)
Red cells 2 (0-2) 3 (0-7)
Time to engraftment
Days of granulocytes <0 .5  109/L 6 (4-7) 7 (3-16)
Days of platelets <50  109/L 2 (2-4) 13 (4-19)
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VGPR after the first procedure [11,12,14,23]. This
observation was not universal, however [24].
Recently, a number of biologic cell modifiers
(thalidomide, bortezomib, or lenalidomide) have been
shown to improvedisease control inpatientswith recur-
rentMMor in theupfront setting [25-27].Nonetheless,
intensified dose melphalan still remains the gold
standard in the treatment of younger patients,
although its place in the therapeutic sequence in the
context of these newer agents is currently being
debated. However, state hospitals in South Africa do
not receive funding for these new agents.
Consequently, we prospectively studied patients with
symptomatic myeloma to determine the effectiveness
of this strategy and establish their outcome after the
combination of Mel 100 and Mel 200 in tandem, each
supported by infusion of autologous stem cells. As our
induction agent we chose dexamethazone, which,
regardless of response, was followed by stem cell
mobilization, stem cell harvest, and then the
ambulatory transplant procedure.
For the mobilization of stem cells, we elected to
use high-dose etoposide as in previous studies it had
been particularly effective in ‘‘poor mobilizers’’ com-
pared to cyclophosphamide [28,29]. This was of
significant relevance, as because of cost constraints,
we wanted to harvest the required progenitor cells
for the 2 transplants with 1 apheresis procedure only.
Additionally, etoposide has potent cytotoxic effects
against malignant plasma cells either in vitro or in
clinical studies and has been included in various
chemotherapeutic schedules [13]. Indeed, sequential
monitoring of some of the disease parameters showed
that after infusion of etoposide, even before the first
treatment of dose intensified Mel, a significant reduc-
tion in the serum paraprotein level was observed, with
consequent improvement of the serum albumin and
blood hemoglobin levels (data not shown). This may
be one of the reasons that after the Mel 100 evaluation
the complete response rate and VGPR were superiorto another study [10,30]. Other reasons could be the
younger age of our population and possible patient
selection bias.
Including a vascular access complication (not
directly related to the study protocol), the overall pro-
cedure mortality was 2%, which is not different from
that of therapy with VAD like combinations or the
experience in other high dose programs. However,
individuals entering such programs must be carefully
evaluated and informed of the possible toxicities
associated with dose intense chemotherapy; 36% of
patients undergoing submyeloablative conditioning
required admission to hospital for the treatment of
intractable nausea, mucositis or neutropenic fever
(Table 3). Provided patients are compliant and closely
monitored, this strategy is feasible in the outpatient
setting; it can considerably reduce the number of
patients who may need to be admitted to hospital
and thus reduce the costs of this program.
Moreover, the outcome after Mel 200 and SCT is
closely related to performance status, which was poor
in most patients presenting to our clinic (median pre-
sentation Karnofsky score of 40%; Figure 1). This,
together with the substantial pressure on our high
care beds, led us to prescribe the first Mel 100 [10] in
the ambulatory setting as a treatment induction step.
At this lower dose nausea and vomiting as well as ‘‘mu-
cositis’’ were less problematic, with minimal treatment
related toxicities and no direct mortality (Figure 1). Of
interest, we noted that responses to Mel 100 appeared
similar to those describedwith the new biologic agents.
To determine the cost effectiveness of this strategy, we
calculated the costs for the conditioningwithMEL100,
together with outpatient therapy with antiemetic
agents, neutropenia prophylaxis, and 3 weekly visits
to the clinic with the corresponding laboratory moni-
toring tests until recovery. We determined that the
median outpatient expenditure from 23 patients was
U.S. $2142.35 (range: 15,441.14-3278.60). The
median admission costs from 11 patients was U.S.
$6042.78 (range: 3900.98-9,786.34), leading to an
overall estimated total expenditure of U.S. $3546.50,
if the average of 10 patients was considered.Thiswould
compare favorably with the cost of induction therapy
with thalidomide (Thalomid; Key Oncologics, South
Africa; R: 10407.12 or U.S. $1387.61per 28 day course
at a dose of 200 mg/day) or bortezomib (Velcade,
Janssen-Ceilag Pharmaceuticals, Johannesburg; R
55,346.92 (U.S. $7379.59) for 3 week cycle), even
without considering other drug additions, the costs of
screening visits and corresponding monitoring labora-
tory investigations. Thus, the cost for the collection of
the additional grafts and outpatient transplantation
after theMel 100 procedure, inclusive of 36% of possi-
ble admissions to hospital, was lower than the single
exit price of 3 months of thalidomide or 1 cycle of
boterzomib. Approximately 4-6 cycles of each strategy
Biol Blood Marrow Transplant 16:1402-1410, 2010 1409Ambulatory Stem Cell Transplantation in Multiple Myelomaare recommended. Mel 100 was well tolerated with no
grade IV (except hematologic) toxicities reported.
On final evaluation at the end of therapy, with this
strategy complete remission occurred in 48% of all
patients, whereas another 33% achieved VGPR and
only 2% had progressive disease. Patients achieving
this favorable response status had a significantly better
survival than those not meeting VGPR criteria
(Figure 2B). These data appear similar to the results
of a larger experience of ‘‘Total Therapy 1’’ by an
Italian group [24]. Nonparametric statistics indicated
that that better median presentation PS score higher
median Hb and achieving CR or VGPR were associ-
ated with longer survival.
There are substantial difficulties in comparing
outcomes of trials inmyeloma because of individual pa-
tient and disease heterogeneity. However, considering
the toxicity of some of the novel agents, the results pre-
sented would suggest that this strategy seem to provide
reasonable compromise between treatment affordability,
effectiveness, and toxicity of the procedure. For com-
munities where the modern biologic cell modifiers
are not readily available, this approach is a cost-effective
option, particularly for those who are responsive to
initial therapy, as response status pre Mel 200 seems
to be important for the post transplantation outcome
[31]. In responders, Mel 200 led to a substantial
improvement in the outcomes compared to Mel 100,
and thus must remain as the preferred intensification
schedule. Last, if the novel agents are accessible, their
incorporation as a maintenance program may provide
greater long-term effectiveness, as previous exposure
has been associated with reduced response, at least in
the relapse setting [13]. Currently there are prospective
trials attempting to define the optimal therapeutic place
for these agents and of the intensified Mel schedules.
The outcome of these studies is eagerly awaited.ACKNOWLEDGMENTS
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